fluoxetine has been researched along with Cardiovascular Diseases in 9 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fluoxetine was the first selective serotonin re-uptake inhibitor to be widely available for treatment of depression and numerous other neuropsychiatric disorders." | 4.82 | Safety and side effect profile of fluoxetine. ( Wernicke, JF, 2004) |
| "The side effect profile and safety of fluoxetine are reviewed." | 3.75 | The side effect profile and safety of fluoxetine. ( Wernicke, JF, 1985) |
| "nortriptyline) was done." | 2.70 | Clinical and treatment response characteristics of late-life depression associated with vascular disease: a pooled analysis of two multicenter trials with sertraline. ( Clary, CM; Doraiswamy, PM; Krishnan, KR, 2001) |
| "Obesity is a major risk factor for morbidity and mortality, and a series of pharmacologic approaches are available for helping to manage the problem." | 2.40 | The pharmacologic approach to the treatment of obesity. ( Abdeen, MA; Frishman, WH; Michaelson, MD; Weiser, M, 1997) |
| " We aimed to characterise the prevalence and seriousness of adverse drug events (ADEs) related to anti-obesity medications and to identify predictors associated with increased risk of serious adverse events (SAE), thereby conveying evidence on drug safety." | 1.91 | A nationwide pharmacovigilance investigation on trends and seriousness of adverse events induced by anti-obesity medication. ( Choi, CY; Choi, YJ; Kim, CU; Shin, S, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, YJ | 1 |
| Choi, CY | 1 |
| Kim, CU | 1 |
| Shin, S | 1 |
| Guo, S | 1 |
| Chen, L | 1 |
| Cheng, S | 1 |
| Xu, H | 1 |
| Harper, A | 1 |
| Wernicke, JF | 2 |
| Weiser, M | 1 |
| Frishman, WH | 1 |
| Michaelson, MD | 1 |
| Abdeen, MA | 1 |
| Strik, JJ | 1 |
| Honig, A | 1 |
| Lousberg, R | 1 |
| Cheriex, EC | 1 |
| Van Praag, HM | 1 |
| Krishnan, KR | 1 |
| Doraiswamy, PM | 1 |
| Clary, CM | 1 |
| Chick, ME | 1 |
5 reviews available for fluoxetine and Cardiovascular Diseases
| Article | Year |
|---|---|
Comparative cardiovascular safety of selective serotonin reuptake inhibitors (SSRIs) among Chinese senile depression patients: A network meta-analysis of randomized controlled trials.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Asian People; Cardiovascular Diseases; China; Citalo | 2019 |
Safety and side effect profile of fluoxetine.
Topics: Adolescent; Adult; Biotransformation; Bipolar Disorder; Cardiovascular Diseases; Child; Comorbidity; | 2004 |
The pharmacologic approach to the treatment of obesity.
Topics: Adrenergic beta-Agonists; Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Energy Metabo | 1997 |
Anesthetic implications for the surgical patient prescribed psychotropic medications.
Topics: Anesthetics; Buspirone; Cardiovascular Diseases; Drug Interactions; Fluoxetine; Humans; Psychotropic | 1992 |
The side effect profile and safety of fluoxetine.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Tricyclic; Cardiovascular Diseases; Clinical | 1985 |
3 trials available for fluoxetine and Cardiovascular Diseases
| Article | Year |
|---|---|
Cardiac side-effects of two selective serotonin reuptake inhibitors in middle-aged and elderly depressed patients.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Depressive Disorder; Double-Blind Method; Echocard | 1998 |
Clinical and treatment response characteristics of late-life depression associated with vascular disease: a pooled analysis of two multicenter trials with sertraline.
Topics: Age of Onset; Aged; Antidepressive Agents; Anxiety; Cardiovascular Diseases; Comorbidity; Depressive | 2001 |
The side effect profile and safety of fluoxetine.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Tricyclic; Cardiovascular Diseases; Clinical | 1985 |
2 other studies available for fluoxetine and Cardiovascular Diseases
| Article | Year |
|---|---|
A nationwide pharmacovigilance investigation on trends and seriousness of adverse events induced by anti-obesity medication.
Topics: Cardiovascular Diseases; Cross-Sectional Studies; Female; Fluoxetine; Humans; Male; Obesity; Pharmac | 2023 |
What is best for the patient?
Topics: Aged; Anxiety Disorders; Cardiovascular Diseases; Dementia; Evidence-Based Medicine; Fluoxetine; Ger | 2003 |